Change in Newron’s Senior Management Team

Milan, Italy – December 23, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, announces that Dennis Dionne, Executive Director for Commercial Operations since 2015, has been appointed to the Company’s Senior Management Team as Vice President Commercial Affairs, effective January 1, 2017.

With more than 25 years of experience, Dennis has been working within the pharmaceutical industry with notable roles, including Senior Sales and Marketing Manager for Johnson & Johnson and Franchise Marketing Director for Novartis. Dennis is based in Newron’s US operations, located in New Jersey.

Dennis Dionne replaces Anders Haegerstrand on the Senior Management Team. Anders will leave the Company effective June 30, 2017, to pursue his professional career outside of Newron.

Stefan Weber, CEO of Newron, commented: “We sincerely thank Anders for his loyalty, dedication and commitment to Newron and wish him all the best for his personal and professional future. At the same time we welcome Dennis as a new member of Newron’s Senior Management Team and are looking forward to continuing to work with him to further develop and execute our global commercial strategy.”

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union and Switzerland and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the US. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing NW-3509 as the potential first addon therapy for the treatment of patients with positive symptoms of schizophrenia.www.newron.com

For more information, please contact

Media

Newron
Stefan Weber – CEO
+39 02 6103 46 26
[email protected]

UK/Europe
Julia Phillip
FTI Consulting
+44 20 3727 1000

Switzerland
Martin Meier-Pfister
IRF Communications
+41 43 244 81 40

Germany
Anne Hennecke
MC Services
+49 211 52925222

USA
Alison Chen
LaVoieHealthScience
+1 617 374 8800, Ext. 104

Investor and Analyst inquiries

Newron
Stefan Weber – CEO
+39 02 6103 46 26
[email protected]

UK/Europe
Julia Phillips
FTI Consulting
+44 20 3727 1000

Switzerland
Martin Meier-Pfister
IRF Communications
+41 43 244 81 40

Germany/Europe
Anne Hennecke
MC Services
+49 211 52925222

USA
Beth Kurth
LaVoieHealthScience
+1 617 374 8800, Ext. 106

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved.

Future events and actual results could differ materially from those set out in, contemplated by or underlying the forwardlooking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements, and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them.

There can be no assurance that actual results of Newron's research programs, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange, where the shares of Newron are listed.

This announcement is not an offer for sale of securities in the United States, Canada, Australia or Japan or any other jurisdiction where such an offer or solicitation would otherwise be unlawful. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Newron does not intend to register any of its securities in the United States or to conduct a public offering of its securities in the United States. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of this document shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.